Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Findling

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2014
Paradoxical Results after Inadvertent Use of Cosyntropin [Adrenocorticotropin Hormone (1-24)] Rather than Acthrel (Ovine Corticotropin Releasing Hormone) during Inferior Petrosal Sinus SamplingTy B Carroll, Amy J H Fisco, Richard J Auchus, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristoneMaria Fleseriu, James W Findling, Christian A Koch, et al.
Journal of the Endocrine Society|September 16, 2020
Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing SyndromeJoshua Kannankeril, Ty Carroll, James W Findling, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2012
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndromeMaria Fleseriu, Beverly M K Biller, James W Findling, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2021
Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary AldosteronismOlivia M DeLozier, Sophie Y Dream, James W Findling, et al.
Journal of the Endocrine Society|July 19, 2021
Response to the Letter to the Editor From Jialal and Sood: "New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency After ACTH Stimulation Using Specific Cortisol Assays"Bradley R Javorsky, Hershel Raff, Ty B Carroll, et al.
The Journal of Surgical Research|April 22, 2022
Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary AldosteronismOlivia M DeLozier, Sophie Dream, James W Findling, et al.
Journal of the Endocrine Society|March 26, 2021
New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol AssaysBradley R Javorsky, Hershel Raff, Ty B Carroll, et al.
The Journal of Clinical Endocrinology and Metabolism|July 30, 2015
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineLynnette K Nieman, Beverly M K Biller, James W Findling, et al.
Endocrine|May 23, 2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide studyJames W Findling, Maria Fleseriu, John Newell-Price, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2014
Paradoxical Results after Inadvertent Use of Cosyntropin [Adrenocorticotropin Hormone (1-24)] Rather than Acthrel (Ovine Corticotropin Releasing Hormone) during Inferior Petrosal Sinus SamplingTy B Carroll, Amy J H Fisco, Richard J Auchus, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristoneMaria Fleseriu, James W Findling, Christian A Koch, et al.
Journal of the Endocrine Society|September 16, 2020
Prospective Evaluation of Late-Night Salivary Cortisol and Cortisone by EIA and LC-MS/MS in Suspected Cushing SyndromeJoshua Kannankeril, Ty Carroll, James W Findling, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2012
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndromeMaria Fleseriu, Beverly M K Biller, James W Findling, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2021
Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary AldosteronismOlivia M DeLozier, Sophie Y Dream, James W Findling, et al.
Journal of the Endocrine Society|July 19, 2021
Response to the Letter to the Editor From Jialal and Sood: "New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency After ACTH Stimulation Using Specific Cortisol Assays"Bradley R Javorsky, Hershel Raff, Ty B Carroll, et al.
The Journal of Surgical Research|April 22, 2022
Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary AldosteronismOlivia M DeLozier, Sophie Dream, James W Findling, et al.
Journal of the Endocrine Society|March 26, 2021
New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol AssaysBradley R Javorsky, Hershel Raff, Ty B Carroll, et al.
The Journal of Clinical Endocrinology and Metabolism|July 30, 2015
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineLynnette K Nieman, Beverly M K Biller, James W Findling, et al.
Endocrine|May 23, 2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide studyJames W Findling, Maria Fleseriu, John Newell-Price, et al.
Pageof 6